Skip to main content
RMTI
NASDAQ Life Sciences

Rockwell Medical Sets 2029 Targets: $100M+ Sales, 30% Gross Margin, No New Fundraising Needed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$7.51
Mkt Cap
$29.642M
52W Low
$4.885
52W High
$21
52W Position info
54% above low
Off High info
64% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

RMTI sits 54% above its 52-week low of $4.885.

Summary

Rockwell Medical's investor presentation sets 2029 targets of $100M+ net sales, $5–10M profitability, and ~30% gross margin, and states no additional fundraising is needed for sustained profitability.


Key Events · Earnings and Guidance · RMTI

  • 2029 Long-Term Targets Set

    By 2029, the company targets net sales above $100 million, profitability of $5–10 million, and gross margin approaching 30%.

  • No Additional Fundraising Required

    The presentation states that no additional fundraising is required to achieve sustained profitability, and projects cash flow positive from operations in 2026 and beyond.

  • 2026 Guidance Reaffirmed

    Reaffirms 2026 guidance: net sales $70–75 million, gross margin 18–22%, adjusted EBITDA $1–2 million.

  • 1H'26 Performance

    First half 2026 net sales of $35.1 million, gross margin of 17%, and adjusted EBITDA of $(0.4) million.


Analysis · RMTI · Life Sciences

The investor presentation introduces new long-term financial targets through 2029 — net sales above $100 million, profitability of $5–10 million, and gross margin approaching 30% — along with a statement that no additional fundraising is required to reach sustained profitability. These forward-looking commitments go beyond the Q2 results already reported today, providing investors with a concrete multi-year framework for the first time.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RMTI was trading at $7.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $4.89 to $21.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RMTI - Latest Insights

RMTI
Nov 12, 2026, 6:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.08
Real-time Price: $6.10 info
Change: -$0.980 (-14%) info
Market Cap: $24.229M info
RMTI
Nov 03, 2026, 4:49 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.09
Real-time Price: $6.10 info
Change: -$1.99 (-25%) info
Market Cap: $24.229M info
RMTI
Nov 03, 2026, 6:00 AM EST
Source: BusinessWire
Importance Score:
9
Price at Filing: $6.91
Real-time Price: $6.10 info
Change: -$0.810 (-12%) info
Market Cap: $24.229M info
RMTI
Aug 13, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.51
Real-time Price: $6.10 info
Change: -$1.41 (-19%) info
Market Cap: $24.229M info
RMTI
Aug 13, 2026, 6:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.51
Real-time Price: $6.10 info
Change: -$1.41 (-19%) info
Market Cap: $24.229M info